)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jiangsu Jibeier Pharmaceutical
Jiangsu Jibeier Pharmaceutical (688566) investor relations material
Jiangsu Jibeier Pharmaceutical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 revenue rose 14.29% YoY to RMB 285.2m; attributable net income increased 61.13% to RMB 76.7m, while 9M reported net income fell 10.66% YoY.
9M adjusted net income increased 14.15% YoY to RMB 175.2m; operating cash flow rose 33.65% to RMB 224.0m.
Q3 financial statements were unaudited.
Financial highlights
9M revenue was RMB 774.7m, up 9.98% YoY; total profit was RMB 200.6m, down 11.88%.
9M attributable net income was RMB 175.9m, down 10.66% YoY; adjusted attributable net income was RMB 175.2m, up 14.15%.
9M operating costs totaled RMB 570.3m versus RMB 526.6m; selling expenses were RMB 382.9m versus RMB 363.6m.
Key financial ratios and metrics
Q3 basic and diluted EPS were RMB 0.38, each up 58.33% YoY; 9M EPS was RMB 0.88, down 11.11%.
Weighted-average ROE was 3.02% for Q3, up 1.01 percentage points; 9M ROE was 7.00%, down 1.46 points.
9M R&D expense was RMB 44.1m, down 15.70% YoY; R&D was 5.69% of revenue, down 1.74 percentage points.
Total assets were RMB 2.882bn at quarter-end, up 6.07% from year-end; parent-attributable equity was RMB 2.550bn, up 4.94%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jiangsu Jibeier Pharmaceutical
- Revenue up 7.6% YoY, net profit down 33.5%, R&D pipeline advanced, dividend proposed.688566
Q2 2026 - Net profit surged 19.28% on 7.76% revenue growth, with strong margins and R&D momentum.688566Q4 2025
- Revenue up 12.2% but net profit and cash flow declined sharply year-over-year.688566Q1 2026
- Revenue up 3.9%, net profit down 5.7%, and R&D spending jumped 64% in Q1 2025.688566Q1 2025
- Nine-month net profit rose 12.80% year-over-year, while Q3 profit declined 9.45%.688566Q3 2025
- Net profit surged 22.4% on steady revenue growth and R&D advances.688566Q2 2025
- Q3 revenue up, but net profit declined on higher R&D; YTD profit and cash flow improved.688566Q3 2024
- Net profit rose 26.74% on steady revenue and robust R&D, with pipeline and financing progress.688566Q2 2024
Next Jiangsu Jibeier Pharmaceutical earnings date
Q4 202628 Apr, 2027
Jiangsu Jibeier Pharmaceutical
Next Jiangsu Jibeier Pharmaceutical earnings date
Q4 202628 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jiangsu Jibeier Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products. The company specializes in treatments for chronic and infectious diseases, providing a portfolio of products that includes antibiotics, antiviral drugs, and health supplements. The company is headquartered in Suzhou, China, and its shares are listed on the Shanghai Stock Exchange.